Office immunotherapy in chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy

Muscle and Nerve

Volumn 52, Issue 4, 2015, Pages 488-497

  Dyck, Peter J ^a   Taylor, Bruce V ^b   Davies, Jenny L ^a   Mauermann, Michelle L ^a   Litchy, William J ^a   Klein, Christopher J ^a   Dyck, P James B ^a  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF TASMANIA   (Australia)

Author keywords

CIDP; Immune therapy; MMN; Neurophysiologic tests; Signs

Indexed keywords

CORTICOSTEROID; IMMUNOGLOBULIN; MYELIN;

ARTICLE; CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY; CORTICOSTEROID THERAPY; DISEASE EXACERBATION; DRUG EFFICACY; HUMAN; IMMUNOTHERAPY; MOTOR NEUROPATHY; NERVE FIBER; PLASMAPHERESIS; PRIORITY JOURNAL; RANKIN SCALE; RANVIER NODE; RELIABILITY; REMISSION; SCHWANN CELL; TREATMENT OUTCOME; TREATMENT RESPONSE; ACTION POTENTIAL; ELECTROMYOGRAPHY; FEMALE; IMMUNOLOGY; MALE; NERVE CONDUCTION; NEUROMUSCULAR DISEASES; PATHOPHYSIOLOGY; PHYSIOLOGY; POLYRADICULONEUROPATHY, CHRONIC INFLAMMATORY DEMYELINATING; PROCEDURES; RETROSPECTIVE STUDY; SEVERITY OF ILLNESS INDEX;

ACTION POTENTIALS; ADRENAL CORTEX HORMONES; ELECTROMYOGRAPHY; FEMALE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOTHERAPY; MALE; NEURAL CONDUCTION; NEUROMUSCULAR DISEASES; PLASMA EXCHANGE; POLYRADICULONEUROPATHY, CHRONIC INFLAMMATORY DEMYELINATING; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84942195805     PISSN: 0148639X     EISSN: 10974598     Source Type: Journal    
DOI: 10.1002/mus.24707     Document Type: Article

References (64)

1. Barohn RJ, Kissel JT, Warmolts JR, Mendell JR. Chronic inflammatory demyelinating polyradiculoneuropathy: clinical characteristics, course, and recommendations for diagnostic criteria. Arch Neurol 1989;46:878-884.
2. Hahn AF, Hartung HP, Dyck PJ. Chronic inflammatory demyelinating polyradiculoneuropathy. In: Dyck PJ, Thomas PK, editors. Peripheral neuropathy, 4th ed. Vol. 2. Philadelphia: Elsevier; 2005. p 2221-2254.
3. Koller H, Kieseier BC, Jander S, Hartung HP. Chronic inflammatory demyelinating polyneuropathy. N Engl J Med 2005;352:1343-1356.
4. Gorson KC, van Schaik IN, Merkies IS, Lewis RA, Barohn RJ, Koski CL, et al. Chronic inflammatory demyelinating polyneuropathy disease activity status: recommendations for clinical research standards and use in clinical practice. J Peripher Nerv Syst 2010;15:326-333.
5. van den Bergh PY, Hadden RD, Bouche P, Cornblath DR, Hahn A, Illa I, et al. European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society-first revision. Eur J Neurol 2010;17:356-363.
6. Dalakas MC. Advances in the diagnosis, pathogenesis and treatment of CIDP. Nat Rev Neurol 2011;7:507-517.
7. Laughlin RS, Dyck PJ, Melton LJ III, Leibson C, Ransom J, Dyck PJ. Incidence and prevalence of CIDP and the association of diabetes mellitus. Neurology 2009;73:39-45.
8. Dyck PJ, Lais AC, Ohta M, Bastron JA, Okazaki H, Groover RV. Chronic inflammatory polyradiculoneuropathy. Mayo Clinic Proc 1975;50:621-637.
9. Dyck PJ, O'Brien PC, Oviatt KF, Dinapoli RP, Daube JR, Bartleson JD, et al. Prednisone improves chronic inflammatory demyelinating polyradiculoneuropathy more than no treatment. Ann Neurol 1982;11:136-141.
10. Molenaar DS, van Doorn PA, Vermeulen M. Pulsed high dose dexamethasone treatment in chronic inflammatory demyelinating polyneuropathy: a pilot study. J Neurol Neurosurg Psychiatry 1997;62:388-390.
11. Lopate G, Pestronk A, Al-Lozi M. Treatment of chronic inflammatory demyelinating polyneuropathy with high-dose intermittent intravenous methylprednisolone. Arch Neurol 2005;62:249-254.
12. Muley SA, Kelkar P, Parry GJ. Treatment of chronic inflammatory demyelinating polyneuropathy with pulsed oral steroids. Arch Neurol 2008;65:1460-1464.
13. van Schaik IN, Eftimov F, van Doorn PA, Brusse E, van den Berg LH, van der Pol WL, et al. Pulsed high-dose dexamethasone versus standard prednisolone treatment for chronic inflammatory demyelinating polyradiculoneuropathy (PREDICT study): a double-blind, randomised, controlled trial. Lancet Neurol 2010;9:245-253.
14. Eftimov F, Vermeulen M, van Doorn PA, Brusse E, van Schaik IN. Long-term remission of CIDP after pulsed dexamethasone or short-term prednisolone treatment. Neurology 2012;78:1079-1084.
15. Boru UT, Erdogan H, Alp R, Tasdemir M, Yildirim S, Bilgic A, et al. Treatment of chronic inflammatory demyelinating polyneuropathy with high dose intravenous methylprednisolone monthly for five years: 10-year follow up. Clin Neurol Neurosurg 2014;118:89-93.
16. Dyck PJ, Daube J, O'Brien P, Pineda A, Low PA, Windebank AJ, et al. Plasma exchange in chronic inflammatory demyelinating polyradiculoneuropathy. N Engl J Med 1986;314:461-465.
17. Ashworth NL, Zochodne DW, Hahn AF, Pillay N, Chalk C, Benstead T, et al. Impact of plasma exchange on indices of demyelination in chronic inflammatory demyelinating polyradiculoneuropathy. Muscle Nerve 2000;23:206-210.
18. Hahn AF, Bolton CF, Pillay N, Chalk C, Benstead T, Bril V, et al. Plasma-exchange therapy in chronic inflammatory demyelinating polyneuropathy. A double-blind, sham-controlled, cross-over study. Brain 1996;119:1055-1066.
19. van Doorn PA, Vermeulen M, Brand A. Intravenous immunoglobulin in treatment of patients with chronic inflammatory demyelinating polyneuropathy. Arch Neurol 1991;48:217-220.
20. Simmons Z, Wald JJ, Albers JW. Chronic inflammatory demyelinating polyradiculoneuropathy in children: II. Long-term follow-up, with comparison to adults. Muscle Nerve 1997;20:1569-1575.
21. Dyck PJ, Litchy WJ, Kratz KM, Suarez GA, Low PA, Pineda AA, et al. A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 1994;36:838-845.
22. Sladky JT. What is the best initial treatment for childhood chronic inflammatory demyelinating polyneuropathy: corticosteroids or intravenous immunoglobulin? Muscle Nerve 2008;38:1638-1643.
23. Hahn AF, Bolton CF, Zochodne D, Feasby TE. Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy. A double-blind, placebo-controlled, cross-over study. Brain 1996;119:1067-1077.
24. Mendell JR, Barohn RJ, Freimer ML, Kissel JT, King W, Nagaraja HN, et al. Randomized controlled trial of IVIg in untreated chronic inflammatory demyelinating polyradiculoneuropathy. Neurology 2001;56:445-449.
25. Hughes R, Bensa S, Willison H, van den Bergh P, Comi G, Illa I, et al. Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 2001;50:195-201.
26. Nobile-Orazio E, Cocito D, Jann S, Uncini A, Beghi E, Messina P, et al. Intravenous immunoglobulin versus intravenous methylprednisolone for chronic inflammatory demyelinating polyradiculoneuropathy: a randomised controlled trial. Lancet Neurol 2012;11:493-502.
27. Midroni G, Dyck PJ. Chronic inflammatory demyelinating polyradiculoneuropathy: unusual clinical features and therapeutic responses. Neurology 1996;46:1206-1212.
28. Dyck PJ, O'Brien PC, Swanson C, Low P, Daube J. Combined azathioprine and prednisone in chronic inflammatory-demyelinating polyneuropathy. Neurology 1985;35:1173-1176.
29. van den Berg LH, Kerkhoff H, Oey PL. Treatment of multifocal motor neuropathy with high-dose intravenous immunoglobulin: a double blind placebo controlled study. J Neurol Neurosurg Psychiatry 1995;59:248-252.
30. Federico P, Zochodne DW, Hahn AF, Brown WF, Feasby TE. Multifocal motor neuropathy improved by IVIg: randomized, double-blind, placebo-controlled study. Neurology 2000;55:1256-1262.
31. Taylor BV, Wright RA, Harper CM, Dyck PJ. Natural history of 46 patients with multifocal motor neuropathy with conduction block. Muscle Nerve 2000;23:900-908.
32. Leger JM, Chassande B, Musset L, Meininger V, Bouche P, Baumann N. Intravenous immunoglobulin therapy in multifocal motor neuropathy: a double-blind, placebo-controlled study. Brain 2001;124:145-153.
33. European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of multifocal motor neuropathy. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society-first revision. J Peripher Nerv Syst 2010;15:295-301.
34. Kyle RA, Therneau TM, Rajkumar SV, Offord JR, Larson DR, Plevak MF, et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med 2002;346:564-569.
35. Dyck PJ, Lambert EH. Polyneuropathy associated with hypothyroidism. J Neuropathol Exp Neurol 1970;29:631-658.
36. Lefaucheur JP, Gregson NA, Gray I, von Raison F, Bertocchi M, Creange A. A variant of multifocal motor neuropathy with acute, generalised presentation and persistent conduction blocks. J Neurol Neurosurg Psychiatry 2003;74:1555-1561.
37. Dyck PJ, Boes CJ, Mulder D, Millikan C, Windebank AJ, et al. History of standard scoring, notation, and summation of neuromuscular signs. A current survey and recommendation. J Peripher Nerv Syst 2005;10:158-172.
38. Dyck PJ, Turner DW, Davies JL, O'Brien PC, Rask CA. Electronic case-report forms of symptoms and impairments of peripheral neuropathy. Can J Neurol Sci 2002;29:258-266.
39. Dyck PJ, Overland CJ, Low PA, Litchy WJ, Davies JL, Dyck PJB, et al. Signs and symptoms versus nerve conduction studies to diagnose diabetic sensorimotor polyneuropathy: Cl vs. NPhys Trial. Muscle Nerve 2010;42:157-164.
40. Dyck PJ, Overland CJ, Low PA, Litchy WJ, Davies JL, Dyck PJB, et al. "Unequivocally Abnormal" vs. "Usual" Signs and Symptoms for Proficient Diagnosis of Diabetic Polyneuropathy Cl vs. N Phys Trial. Arch Neurol 2012;69:1609-1614.
41. O'Brien PC, Dyck PJ. Procedures for setting normal values. Neurology 1995;45:17-23.
42. Dyck PJ, Litchy WJ, Lehman KA, Hokanson JL, Low PA, O'Brien PC. Variables influencing neuropathic endpoints: the Rochester Diabetic Neuropathy Study of Healthy Subjects (RDNS-HS). Neurology 1995;45:1115-1121.
43. Dyck PJ, Hughes RAC, O'Brien PC. Quantitating overall neuropathic symptoms, impairments, and outcomes. In: Dyck PJ, Thomas PK, editors. Peripheral neuropathy, 4th ed. Philadelphia: Elsevier; 2005. p 1031-1052.
44. Dyck PJ, Albers JW, Wolfe J, Bolton CF, Walsh N, Klein CJ, et al. A trial of proficiency of nerve conduction: greater standardization still needed. Muscle Nerve 2013;48:369-374.
45. Litchy WJ, Albers JW, Wolfe J, Bolton CF, Walsh N, Klein CJ, et al. Proficiency of nerve conduction using standard methods and reference values (Trial 4). Muscle Nerve 2014;50:900-908.
46. Dyck PJ, Argyros B, Russell JW, Gahnstrom LE, Nalepa S, Albers JW, et al. Multicenter trial of the proficiency of smart quantitative sensation tests. Muscle Nerve 2014;49:645-653.
47. Dyck PJ, Herrmann DN, Staff NP, Dyck PJB. Assessing decreased sensation and increased sensory phenomena in diabetic polyneuropathies. Diabetes 2013;62:3677-3686.
48. Suanprasert N, Berk JL, Benson MD, Dyck PJB, Klein CJ, Gollob JA, et al. Retrospective study of a TTR FAP cohort to modify NIS + 7 for therapeutic trials. J Neurol Sci 2014;344:121-128.
49. Dyck PJ, Low PA, Windebank AJ, Jaradeh SS, Gosselin S, Bourque P, et al. Plasma exchange in polyneuropathy associated with monoclonal gammopathy of undetermined significance. N Engl J Med 1991;325:1482-1486.
50. Nevo Y, Pestronk A, Kornberg AJ, Connolly AM, Yee WC, Iqbal I, et al. Childhood chronic inflammatory demyelinating neuropathies: clinical course and long-term follow-up. Neurology 1996;47:98-102.
51. Sghirlanzoni A, Solari A, Ciano C, Mariotti C, Fallica E, Pareyson D. Chronic inflammatory demyelinating polyradiculoneuropathy: long-term course and treatment of 60 patients. Neurol Sci 2000;21:31-37.
52. Kuwabara S, Misawa S, Mori M, Tamura N, Kubota M, Hattori T. Long term prognosis of chronic inflammatory demyelinating polyneuropathy: a five year follow up of 38 cases. J Neurol Neurosurg Psychiatry 2006;77:66-70.
53. Priori A, Cinnante C, Pesenti A, Carpo M, Cappellari A, Nobile-Orazio E, et al. Distinctive abnormalities of motor axonal strength-duration properties in multifocal motor neuropathy and in motor neurone disease. Brain 2002;125:2481-2490.
54. Kiernan MC, Guglielmi JM, Kaji R, Murray NM, Bostock H. Evidence for axonal membrane hyperpolarization in multifocal motor neuropathy with conduction block. Brain 2002;125:664-675.
55. Kaji R. Physiology of conduction block in multifocal motor neuropathy and other demyelinating neuropathies. Muscle Nerve 2003;27:285-296.
56. Vlam L, van der Pol WL, Cats EA, Straver DC, Piepers S, Franssen H, et al. Mulitfocal motor neuropathy: diagnosis, pathogenesis and treatment strategies. Nat Rev Neurol 2012;8:48-58.
57. Priori A, Bossi B, Ardolino G, Bertolasi L, Carpo M, Nobile-Orazio E, et al. Pathophysiological heterogeneity of conduction blocks in multifocal motor neuropathy. Brain 2005;128:1642-1648.
58. Susuki K, Rasband MN, Tohyama K, Koibuchi K, Okamoto S, Funakoshi K, et al. Anti-GM1 antibodies cause complement-mediated disruption of sodium channel clusters in peripheral motor nerve fibers. J Neurosci 2007;27:3956-3967.
59. Susuki K, Baba H, Tohyama K, Kanai K, Kuwabara S, Hirata K, et al. Gangliosides contribute to stability of paranodal junctions and ion channel clusters in myelinated nerve fibers. Glia 2007;55:746-757.
60. Piepers S, Jansen MD, Cats EA, van Sorge NM, van den Berg LH, van der Pol WL. IVIg inhibits classical pathway activity and anti-GM1 IgM-mediated complement deposition in MMN. J Neuroimmunol 2010;229:256-262.
61. Yuki N, Watanabe H, Nakajima T, Spath PJ. IVIG blocks complement deposition mediated by anti-GM1 antibodies in multifocal motor neuropathy. J Neurol Neurosurg Psychiatry 2011;82:87-91.
62. Willison HJ, Galban-Horcajo F, Halstead SK. Antibodies to GM1: galactocerebroside complexes in multifocal motor neuropathy: it takes two to tango. J Neurol Neurosurg Psychiatry 2014;85:715.
63. Nobile-Orazio E, Giannotta C, Musset L, Messina P, Leger JM. Sensitivity and predictive value of anti-GM1/galactocerebroside IgM antibodies in multifocal motor neuropathy. J Neurol Neurosurg Psychiatry 2014;85:754-758.
64. Taylor BV, Dyck PJB, Engelstad J, Gruener G, Grant I, Dyck PJ. Multifocal motor neuropathy: pathologic alterations at the site of conduction block. J Neuropathol Exp Neurol 2004;63:129-137.